Clinical Trials Directory

Trials / Completed

CompletedNCT00578721

Trial of Aspirin and Arginine Restriction in Colorectal Cancer

Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Colorectal Cancer Patients

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
24 (actual)
Sponsor
University of California, Irvine · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this research study is to understand the effects of oral aspirin taken daily with an arginine-restricted diet on certain colorectal cancer biomarkers in treated colorectal cancer patients. Patients with colorectal cancer are at high risk for recurrence and for development of secondary colorectal cancers in the future. Specific chemicals (polyamines, prostaglandins) in the body referred to as biomarkers can be measured to help understand a person's risk for developing colorectal cancer. Specific biomarkers associated with colorectal cancer have been identified in prior laboratory studies. By measuring these predefined biomarkers before and after the study intervention, we can assess how they are affected by the intervention, and gain knowledge about their usefulness in colorectal cancer patients on clinical trial. This study is a Phase IIa clinical biomarker study, using oral aspirin 325 mg taken daily with an arginine-restricted diet designed to reduce arginine intake by at least 30% during the 12-week study period. The biomarkers will be obtained from patient by performing endoscopy (a procedure used to look at the inside of the bowel, rectum and colon) and biopsy (taking samples of tissue), phlebotomy (drawing blood), and urine collection. Biopsies are done to evaluate changes in tissue content that may relate to early events in colon cancer formation. This was the procedure used to diagnose your condition initially. There will be 24 patients enrolled into this study performed through University of California Irvine Medical Center.

Conditions

Interventions

TypeNameDescription
DRUGAspirin325 mg taken daily with an arginine-restricted diet

Timeline

Start date
2008-09-24
Primary completion
2013-11-26
Completion
2013-11-26
First posted
2007-12-21
Last updated
2023-07-07
Results posted
2023-06-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00578721. Inclusion in this directory is not an endorsement.